Cellular reprogramming.
Nuclear reprogramming technology was first established more than 50 years ago. It can rejuvenate somatic cells by erasing the epigenetic memories and reconstructing a new pluripotent order. The recent discovery reviewed here that induced pluripotency can be achieved by a small set of transcription factors has opened up unprecedented opportunities in the pharmaceutical industry, the clinic, and laboratories. This technology allows us to access pathological studies by using patient-specific induced pluripotent stem (iPS) cells. In addition, iPS cells are also expected to be a rising star for regenerative medicine, as sources of transplantation therapy.
Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan.
Kazutoshi
K
Takahashi
D002454:Cell Differentiation / Q000235:genetics / Q000502:physiology*; D065150:Cellular Reprogramming / Q000235:genetics / Q000502:physiology*; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology / Q000502:physiology*; D017570:MyoD Protein / Q000235:genetics / Q000502:physiology; D014157:Transcription Factors / Q000235:genetics / Q000502:physiology*
D017570:MyoD Protein; C057363:MyoD1 myogenic differentiation protein; D014157:Transcription Factors